SCHEMBL191334

SCHEMBL191334

Cc1noc(Cc2cc(Nc3nc(CCc4ccccc4)cs3)ncc2Br)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.41
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
AOC3 Q16853 3/20 0.35
INSR P06213 1/20 0.34
IGF1R P08069 1/20 0.34
FGFR1 P11362 1/20 0.34
KDR P35968 1/20 0.34
GLS O94925 1/20 0.34
MAOB P27338 2/20 0.34
NOS1 P29475 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190789 0.87 GCK (0.42) GCKNPC1RAB9AAOC3INSR
SCHEMBL190677 0.86 GCK (0.41) GCKNPC1RAB9AL3MBTL1AOC3
SCHEMBL190604 0.78 GAA (0.43) GCKNPC1RAB9AAOC3MAOB
SCHEMBL191430 0.77 LMNA (0.46) NPC1RAB9AMAPK1TDP1MEN1
SCHEMBL191596 0.77 GCK (0.44) GCKNPC1RAB9AAOC3MAOB
SCHEMBL192244 0.77 GCK (0.44) GCKNPC1RAB9AL3MBTL1AOC3
SCHEMBL192556 0.76 AOC3 (0.38) GCKAOC3MAOBNOS1
SCHEMBL191480 0.76 GCK (0.54) GCKAOC3NOS1
Hydrochloric Acid SCHEMBL191165 0.76 GCK (0.43) GCKNPC1RAB9AL3MBTL1AOC3
SCHEMBL191341 0.75 MEN1 (0.43) GCKNPC1RAB9AMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885NPC1 1862/4885RAB9A 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.